Schizophrenia and Bipolar Disorder

TL;DR. These are the two conditions that shaped how societies think about mental illness, and both are widely misunderstood. Schizophrenia is not a split personality; it is a disorder in which the brain's ability to distinguish internally generated experience from external reality breaks down, producing hallucinations and delusions, alongside a quieter and more disabling loss of motivation, expression, and cognitive sharpness. Bipolar disorder is not moodiness; it is episodes of mania, a state of elevated or irritable mood with reduced need for sleep, racing thought, and impaired judgement, alternating with depression. Both are treatable, both allow recovery in a substantial proportion of people, and both are associated with a life expectancy gap of 10 to 20 years driven mostly by physical illness and suicide rather than by the psychiatric symptoms themselves.

Key takeaways

• Schizophrenia affects roughly 24 million people, about 1 in 300, with onset typically in late adolescence or early adulthood, earlier in men.
• The negative symptoms (reduced motivation, flat expression, social withdrawal) and cognitive symptoms predict functional outcome better than hallucinations and delusions, and they respond poorly to existing drugs.
• Schizophrenia is roughly 80 percent heritable and highly polygenic. The strongest single finding implicates complement component 4 and excessive synaptic pruning in adolescence.
• Clozapine is substantially more effective than any other antipsychotic in treatment-resistant schizophrenia, and it is underused because it requires blood monitoring.
• Lithium remains the most effective treatment for bipolar disorder after 75 years, and it is the only psychiatric drug with good evidence of reducing suicide.
• Antidepressants alone can precipitate mania in bipolar disorder, which is why distinguishing bipolar depression from unipolar depression matters clinically.

Part 1: Schizophrenia

What it is

In short: Three symptom groups, and the quiet ones (lost motivation and expression) predict how life goes better than the hallucinations do.

Schizophrenia is diagnosed on the presence, for at least six months, of characteristic symptoms with significant functional impairment. Symptoms fall into three groups.

Positive symptoms (present, but should not be):

• Hallucinations, most often auditory: voices commenting, conversing, or commanding. They are heard as genuinely external, and telling someone the voices are not real is about as useful as telling someone their headache is not real.
• Delusions: fixed false beliefs held despite contrary evidence. Persecutory delusions are commonest; also grandiose, referential (broadcasts or strangers are communicating with you), and delusions of control.
• Disorganised thinking, evident in speech that derails, becomes tangential, or in extreme cases incoherent.
• Disorganised or catatonic behaviour.

Negative symptoms (absent, but should not be): reduced emotional expression, reduced speech (alogia), loss of motivation and goal-directed behaviour (avolition), reduced capacity for pleasure (anhedonia), social withdrawal. These are frequently mistaken for laziness or depression, they cause most of the long-term disability, and current drugs barely touch them.

Cognitive symptoms: impaired working memory, attention, processing speed, and executive function, often present before the first psychotic episode.

Don't be confused: schizophrenia is not "split personality." The name, coined by Eugen Bleuler in 1908, means "split mind" and referred to the fragmentation of thought, emotion, and perception within one mind, not multiple personalities. Dissociative identity disorder is a completely separate and much rarer condition. The confusion has been remarkably durable and it distorts public understanding of what is a disorder of perception and thought, not of identity.

A second correction worth making bluntly: people with schizophrenia are far more likely to be victims of violence than perpetrators of it. The population-attributable risk of violence from schizophrenia is small, is concentrated in untreated psychosis combined with substance use, and is dwarfed by alcohol as a driver of violence in the general population.

The history

In short: From lobotomy to a 1952 antihistamine that emptied the asylums, and a 2016 genetic finding that finally connected a gene to a developmental theory.

Descriptions of psychosis are ancient. Emil Kraepelin in the 1890s separated dementia praecox (early-onset, deteriorating) from manic-depressive insanity (episodic, with recovery between episodes), a division that still structures psychiatry. Eugen Bleuler renamed the first schizophrenia in 1908 and argued the course was less uniformly deteriorating than Kraepelin thought, which turned out to be correct.

Treatment history is grim and then abruptly better. Asylums grew through the nineteenth century. The first half of the twentieth produced insulin coma therapy, fever therapy, and prefrontal lobotomy, for which Egas Moniz received a Nobel Prize in 1949 and which was performed on tens of thousands of people, often with devastating results.

1952: chlorpromazine, developed as an antihistamine and anaesthetic adjunct, was found to calm psychotic agitation and reduce hallucinations and delusions. Within a decade it had changed psychiatric practice worldwide and enabled deinstitutionalisation, a process that liberated many people and, where community services were not funded to match, left many others homeless or in prison.

1958 to 1970s: clozapine developed, briefly withdrawn after fatal agranulocytosis, then reintroduced in 1989 with mandatory blood monitoring after being shown clearly superior in treatment-resistant patients. 1963: the dopamine hypothesis is proposed after Arvid Carlsson shows antipsychotics block dopamine receptors.

2016: Sekar and colleagues identify variation in the complement component 4 (C4) gene as the strongest genetic association, and link it to synaptic pruning, providing the first mechanistic bridge from a genetic finding to a developmental theory of the disease.

2024: xanomeline-trospium approved, the first antipsychotic with a genuinely new mechanism (muscarinic receptor agonism) in over seventy years.

What actually goes wrong

In short: Excess dopamine signalling attaches significance to irrelevant things, and delusions are the mind's attempt to explain that feeling.

Dopamine. All effective antipsychotics block dopamine D2 receptors, and drugs that increase dopamine (amphetamines, high-dose levodopa) can produce psychosis. Imaging shows increased presynaptic dopamine synthesis in the striatum in psychosis. The refined version of the hypothesis is about aberrant salience: dopamine signals "this is important, attend to this," and excess dopamine signalling attaches significance to irrelevant stimuli. A parked car, a phrase on the radio, a stranger's glance all feel loaded with meaning, and delusions are the mind's attempt to explain a persistent, unwarranted sense of significance. That model explains why antipsychotics dampen the conviction and distress before the beliefs themselves fade.

Glutamate. Dopamine cannot be the whole story, because negative and cognitive symptoms respond poorly to D2 blockade. NMDA receptor antagonists (ketamine, phencyclidine) reproduce positive, negative, and cognitive symptoms in healthy people far more faithfully than amphetamine does, which implicates glutamate signalling and NMDA receptor hypofunction on inhibitory interneurons.

Development. Schizophrenia is increasingly understood as a neurodevelopmental disorder with a late clinical onset. Subtle motor and cognitive differences are detectable in childhood years before psychosis. The C4 finding fits: complement proteins tag synapses for elimination by microglia, adolescence is a period of intense synaptic pruning in the prefrontal cortex, and excessive pruning would explain both the timing of onset and the reduced cortical grey matter and dendritic spine density seen post mortem.

Risk factors:

What it does to the body and to a life

In short: A 15 to 20 year life expectancy gap, roughly two-thirds of it from physical illness that is measurably under-treated.

Untreated psychosis is frightening and exhausting. Beyond that, the disease imposes:

• Functional loss: education interrupted at exactly the age it matters, employment rates low, relationships disrupted.
• Cognitive impairment, which is the strongest predictor of whether someone works.
• Suicide: lifetime risk around 5 percent, highest in the early years after diagnosis and in people with good insight into what they have lost.
• Physical health: people with schizophrenia die 15 to 20 years earlier than average. Roughly two-thirds of that gap is cardiovascular and metabolic disease, driven by very high smoking rates (around 60 to 80 percent), antipsychotic-induced weight gain and diabetes, poverty, and demonstrably worse physical healthcare, with fewer investigations and interventions offered for the same presenting complaints, a phenomenon called diagnostic overshadowing.

Outcomes are better than the stereotype. Long-term follow-up studies find roughly a third have good outcomes with substantial recovery, a third intermediate, and a third poor. Duration of untreated psychosis predicts outcome, which is the entire rationale for early intervention services.

Treatment, and how it works

In short: Antipsychotics treat the hallucinations well and the disabling symptoms poorly, and clozapine is far more effective than the rest and prescribed far too late.

Antipsychotics block D2 dopamine receptors, reducing the aberrant salience signalling. First generation drugs (haloperidol, chlorpromazine) block D2 strongly and cause more movement side effects. Second generation drugs (olanzapine, risperidone, quetiapine, aripiprazole) have additional serotonin receptor actions, cause fewer movement effects, and cause more metabolic ones. Aripiprazole is a partial agonist, stabilising rather than blocking.

They reduce positive symptoms well, negative and cognitive symptoms poorly. Continuing them substantially reduces relapse; stopping is the commonest cause of relapse.

Clozapine is the exception in efficacy. In treatment-resistant schizophrenia (failure of two adequate antipsychotic trials), response rates are around 30 to 60 percent where other drugs have failed, and it also reduces suicide. It requires regular blood counts because it causes agranulocytosis (loss of neutrophils) in roughly 1 percent, which is potentially fatal and detectable in time by monitoring. It also causes sedation, weight gain, hypersalivation, constipation that can become life-threatening, and rarely myocarditis. Despite the clear evidence, clozapine is prescribed to far fewer eligible patients than guidelines recommend, and usually years later than it should be, which is a well-documented quality failure.

Long-acting injectable formulations (given every 2 to 12 weeks) reduce relapse driven by missed doses, and are underused partly because they were historically associated with coercion.

Psychosocial treatment is not optional:

• Early intervention services: specialist multidisciplinary teams for the first few years after a first episode. They improve symptoms, relapse rates, employment, and engagement, and they are cost-effective.
• CBT for psychosis: works on the distress and conviction attached to voices and beliefs rather than arguing about their truth.
• Family intervention: reduces relapse substantially, one of the best-evidenced interventions in the field.
• Supported employment (individual placement and support): places people in real jobs with ongoing support rather than pre-training them indefinitely, and outperforms traditional vocational rehabilitation consistently.
• Assertive community treatment for those with repeated crises.

Side effects to know:

Part 2: Bipolar disorder

What it is

In short: Defined by mania rather than by low mood, which is why it is missed for years when people present only when depressed.

Bipolar disorder is defined by episodes of mania or hypomania, usually alternating with depression.

Mania: at least a week (or any duration if hospitalisation is needed) of abnormally elevated, expansive, or irritable mood with increased activity, plus several of: inflated self-esteem or grandiosity, markedly decreased need for sleep (feeling rested after three hours, which is different from insomnia), pressured speech, racing thoughts, distractibility, increased goal-directed activity, and involvement in activities with high potential for painful consequences (spending sprees, sexual indiscretion, reckless business decisions). Psychosis can occur.

Hypomania is the same picture, milder, at least four days, without marked impairment or psychosis.

People with bipolar disorder spend far more time depressed than manic, which is why the diagnosis is missed for years: they present when depressed, and nobody asks about the periods when they felt unusually good, needed no sleep, and got a great deal done. Average delay from first symptoms to correct diagnosis is often measured in years.

What actually goes wrong

Less is established than for schizophrenia. What is reasonably clear:

• Genetics: heritability around 60 to 85 percent, polygenic, with substantial genetic overlap with schizophrenia, which undercuts the sharp Kraepelinian division.
• Circadian rhythm disturbance: sleep loss can precipitate mania, and mania reduces sleep, which is a self-amplifying loop. Regular sleep and daily routine are genuinely therapeutic, and social rhythm therapy is built on this.
• Neurotransmitter and signalling changes: dopamine hyperactivity in mania, and intracellular signalling pathways affected by lithium and valproate, though which effect is therapeutic is unresolved.
• Kindling: episodes may become more frequent and less clearly triggered over time, which is part of the argument for early and continuous treatment.

Is it deadly?

Bipolar disorder carries one of the highest suicide risks in psychiatry: lifetime risk on the order of 6 to 7 percent, roughly 20 times the general population rate, concentrated in depressive and mixed states. Life expectancy is reduced by roughly 10 to 20 years, again mostly through cardiovascular disease, substance use, and suicide.

Mania itself causes harm through its consequences: financial ruin, damaged relationships, legal problems, and physical exhaustion, all decided in a state that feels, from the inside, like clarity.

Treatment, and how it works

In short: Lithium remains the most effective option after 75 years and is the only psychiatric drug with good evidence of reducing suicide.

Lithium. Discovered by John Cade in 1949 in Australia (he was injecting guinea pigs with urine from manic patients and used lithium urate to dissolve the uric acid, noticing the animals became placid, a chain of reasoning that was wrong in nearly every particular and produced the right answer). It remains the most effective long-term treatment: it reduces both manic and depressive relapses, and it is the only psychiatric medication with reasonable evidence of reducing suicide specifically, beyond its mood effects. Its mechanism is still not settled, with inositol depletion and GSK-3 inhibition the leading candidates.

Lithium has a narrow therapeutic index, requiring blood level monitoring, and it affects the thyroid and kidneys over the long term. Dehydration, NSAIDs, ACE inhibitors, and diuretics can push levels into toxicity, which presents with tremor, vomiting, confusion, and can be life-threatening. It is nonetheless underprescribed relative to its evidence, partly because monitoring is inconvenient and partly because it is old and unpromoted.

Other mood stabilisers:

• Valproate: effective in mania, and subject to the pregnancy restrictions described in Chapter 39. It should generally not be used in women of childbearing potential.
• Lamotrigine: effective in preventing the depressive pole rather than the manic one. Requires slow dose escalation because of rash risk.
• Second generation antipsychotics (quetiapine, olanzapine, aripiprazole, lurasidone, cariprazine): used in acute mania, in bipolar depression, and for maintenance.
• ECT: highly effective in severe mania and bipolar depression, and in mixed states.

Antidepressants are the contested part. Given alone in bipolar disorder they can precipitate mania or rapid cycling, and their efficacy in bipolar depression is weak in trials. Standard practice is to avoid them alone, and to use them only with a mood stabiliser if at all. This is why distinguishing bipolar from unipolar depression matters: the same presenting complaint gets different treatment, and getting it wrong can make someone considerably worse.

Psychological and practical treatment: psychoeducation (which has good evidence for relapse prevention), identifying individual early warning signs and having a written plan, protecting sleep and routine, avoiding stimulants and alcohol, and family involvement. Advance statements, written while well, specifying preferences for treatment during a future episode, are valuable and underused.

Who gets it

Around 40 to 60 million people worldwide. Onset typically in late adolescence to mid-twenties. Roughly equal in men and women, though bipolar II and rapid cycling are more common in women. Family history is the strongest risk factor. Childbirth is a specific high-risk period: postpartum psychosis, which occurs in roughly 1 to 2 per 1,000 deliveries and far more often in women with bipolar disorder, is a psychiatric emergency.

On the creativity association: there is a real, replicated statistical association between bipolar disorder and creative professions in large registry studies, and it is regularly inflated into romanticism. The effect is modest, most people with bipolar disorder are not unusually creative, most creative people do not have it, and the illness's consequences are severe. People sometimes stop treatment believing it dulls their abilities; untreated mania destroys careers far more reliably than lithium does.

What the person can do

In short: Treat sleep as medical, avoid cannabis and stimulants, get physical health monitored, and write down your early warning signs while well.

For both conditions:

• Treat sleep as medical. Sleep loss precipitates mania and worsens psychosis. Regular timing matters more than duration.
• Avoid cannabis and stimulants. Both worsen psychosis and destabilise mood, and cannabis use is one of the most consistent predictors of relapse.
• Stop smoking, with support, since smoking accounts for much of the mortality gap and quitting is achievable with the same treatments that work for anyone else.
• Get physical health monitored: weight, blood pressure, glucose, and lipids at least annually. This is standard guidance and frequently not done.
• Learn your early warning signs and write them down while well, together with what should happen if they appear and who should be contacted.
• Involve family or a trusted person with your consent, since relapse is often visible to others before it is to you.
• Do not stop medication abruptly. Abrupt lithium discontinuation in particular is associated with a high risk of rapid relapse.

What's next

In short: A genuinely new antipsychotic mechanism after seventy years, and a large gap between best evidence and average practice that needs no new science to close.

• Muscarinic agonists: xanomeline-trospium, approved in 2024, is the first genuinely new antipsychotic mechanism since the 1950s and works without D2 blockade, which means it does not cause the movement or prolactin side effects. Other muscarinic agents are in development.
• Treating negative and cognitive symptoms, the largest unmet need in schizophrenia and the area where drug development has repeatedly failed.
• Early detection and prevention in clinical high-risk states, where the field is trying to work out whether intervening before a first episode changes trajectories.
• Better use of what exists: earlier clozapine, more long-acting injectables, universal early intervention services, and physical health care that treats people with severe mental illness as though their bodies matter. The gap between best evidence and average practice is larger here than in almost any other area of medicine.
• Genomics-informed subtyping, since both conditions are almost certainly collections of disorders sharing a final common presentation.

Sources and notes

Schizophrenia prevalence (approximately 24 million people, about 1 in 300) is WHO. Life expectancy gap: Hjorthøj et al., Lancet Psychiatry, 2017. Heritability estimates: Sullivan et al. and Lichtenstein et al. twin and registry studies. C4 and synaptic pruning: Sekar et al., Nature, 2016. Aberrant salience: Kapur, American Journal of Psychiatry, 2003. Clozapine superiority: Kane et al., 1988, and subsequent meta-analyses; underuse documented in multiple health system audits. Cannabis and psychosis: Di Forti et al., Lancet Psychiatry, 2019. Migration and psychosis risk: Cantor-Graae and Selten, American Journal of Psychiatry, 2005. Violence risk: Fazel et al., PLoS Medicine, 2009. Lithium discovery: Cade, Medical Journal of Australia, 1949; anti-suicide effect: Cipriani et al., BMJ, 2013. Bipolar suicide risk: Plans et al., Journal of Affective Disorders, 2019. Creativity association: Kyaga et al., Journal of Psychiatric Research, 2013. Xanomeline-trospium: EMERGENT trials, 2023 to 2024.

Open questions. Whether schizophrenia is one disease or many is unresolved, as is the relationship between it and bipolar disorder given their genetic overlap. No treatment meaningfully improves negative or cognitive symptoms. Whether intervening in high-risk states prevents psychosis is unproven.

Next: the disorder that sits at the intersection of biology, choice, and policy. 👉